Form 4: ANAB Director Converts RSUs to Common Stock

ANAPTYSBIO Director John A. Orwin converted 1,300 restricted stock units into common stock, increasing his direct holdings to 10,665 shares.

Summary

• John A. Orwin, a Director of ANAPTYSBIO, INC. (ANAB), converted 1,300 Restricted Stock Units (RSUs) into shares of the company's common stock.
• This transaction occurred on September 15, 2025, and resulted in the acquisition of 1,300 shares of common stock for no consideration.
• Following this conversion, Orwin directly holds 10,665 shares of ANAPTYSBIO common stock.
• The converted RSUs were part of a grant that vests in three equal tranches, with this conversion representing the second tranche.
• Orwin still holds 1,300 unvested Restricted Stock Units, which are scheduled to vest on September 15, 2026, subject to continued service.

Sentiment

Score: 7

Explanation: The filing reports a routine, pre-scheduled RSU conversion by a director, which is generally a neutral to slightly positive event as it increases insider ownership and reflects the fulfillment of compensation terms.

Positives

• Director John A. Orwin increased his direct ownership of common stock by 1,300 shares, demonstrating continued alignment with shareholder interests.
• The conversion of Restricted Stock Units into common stock for no consideration is a standard compensation practice, indicating the fulfillment of vesting conditions.

Negatives

• No explicit negatives are present in this routine insider transaction filing.

Risks

• No specific risks are mentioned in this Form 4 filing, which primarily reports a change in beneficial ownership.

Future Outlook

The filing indicates that 1,300 Restricted Stock Units are still held by Director John A. Orwin and are scheduled to vest on September 15, 2026, subject to continued service to the company.

Industry Context

This is a routine insider transaction (RSU vesting and conversion) common across publicly traded companies, particularly in the biotechnology sector, as a form of executive compensation and retention. It does not provide broader industry trends.

Comparison to Industry Standards

• The conversion of Restricted Stock Units (RSUs) into common stock upon vesting is a standard practice for executive and director compensation across various industries, including biotechnology. This aligns with typical equity incentive plans designed to align management interests with shareholder value over time. No specific comparable companies or projects are mentioned in the filing.

Related Party Transactions

• The RSU conversion is a compensation-related transaction with a director, which is a form of related-party transaction, but it is a standard, disclosed compensation event.

Stakeholder Impact

• Shareholders: Increased direct ownership by a director may be viewed positively as it aligns management interests with shareholder value.
• Employees: No direct impact on general employees.
• Management: The director received compensation in the form of common stock, fulfilling a part of his equity incentive plan.

Next Steps

• The remaining 1,300 Restricted Stock Units held by John A. Orwin are scheduled to vest on September 15, 2026, contingent on his continued service to the company.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-scheduled conversion of Restricted Stock Units (RSUs) into common stock by a director. Such transactions are standard compensation events and do not typically provide new fundamental information that would warrant a change in investment recommendation. The increase in direct insider ownership is a minor positive, but not significant enough to alter a broader investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining existing positions based on the company's overall fundamentals rather than this specific insider transaction.

Keywords

ANAPTYSBIO, ANAB, John A Orwin, Director, Form 4, SEC filing, insider transaction, RSU conversion, common stock, beneficial ownership